Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 27;102(9):1415-21.
doi: 10.1038/sj.bjc.6605636. Epub 2010 Apr 6.

Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study

M C Bradley  1 , C M Hughes, M M Cantwell, G Napolitano, L J Murray
Affiliations

Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study

M C Bradley et al. Br J Cancer. .

Abstract

Background: Non-steroidal anti-inflammatory drug (NSAID) use has been linked with pancreatic cancer risk; however, findings from epidemiological studies are inconsistent.

Methods: A nested case-control study was conducted within the UK General Practice Research Database. Cases (n=1141) had a diagnosis of primary cancer of the exocrine pancreas between January 1995 and June 2006. Controls (n=7954) were matched with each case on general practice site, sex and year of birth. Conditional logistic regression analyses were used to generate odds ratios (OR) and 95% confidence intervals (CI) associated with NSAID use compared with non-use.

Results: Any use of NSAID in the 5 years before the index date or since entry into the database (excluding the year before diagnosis) was not associated with risk of pancreatic cancer; OR 0.96 (95% CI, 0.84-1.10) and 1.03 (95% CI 0.89-1.19), respectively. Exposure to NSAIDs for > 773 days, in the 5 years pre-diagnosis, was associated with a reduced risk of pancreatic cancer OR 0.78 (95%CI 0.62-0.97). There was evidence of reduced pancreatic cancer risk with long-term use (5 years or more) of lower doses of NSAIDs OR 0.70 (95% CI 0.49-0.99).

Conclusion: Long-term exposure to NSAIDs may be associated with a reduction in risk of pancreatic cancer.

PubMed Disclaimer

References

    1. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A (2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100: 551–557 - PMC - PubMed
    1. Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002a) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94: 1168–1171 - PubMed
    1. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885–895 - PubMed
    1. Arellano F, Yood M, Wentworth C, Oliveria S, Rivero E, Verma A, Rothman K (2006) Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription nonsteroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 15: 861–872 - PubMed
    1. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, APPROVe Trial Investigators (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674–1682 - PubMed

Publication types

Substances